Spectral Medical Inc T.EDT

Spectral on Linkedin Today

[TechOne]

Research indicates that elevated hashtag#endotoxin levels correlate with disease severity and patient outcomes, making EAA a valuable tool in clinical settings.

The endotoxin activity assay (EAA) has confirmed the link between systemic LPS presence and Gram-negative infections in hospitalized patients.

In the MEDIC trial, the EAA demonstrated a sensitivity of 85.3% for detecting Gram-negative infections and a negative predictive value of 98.6% for ruling them out.

Endotoxemia was also found in patients with Gram-positive infections and those without culture-positive organisms, suggesting LPS may translocate from the gut.

High levels of endotoxin (EA ≥0.6) were associated with an increased risk of severe hashtag#sepsis and ICU mortality.

The EAA can help identify patients who may benefit from anti-endotoxin therapies, as seen in preliminary studies combining EAA with hemoperfusion devices.

The assay is useful in ruling out Gram-negative infections in ICU patients presenting with systemic inflammatory responses without clear infection sources.

The combination of diagnostic assays with specific therapeutic agents may enhance treatment efficacy and patient selection

https://buff.ly/3Bfc38v

[hmmmmmmmm]

Correct me if I'm wrong, but it does seem all their posts/ claims on LinkedIn are re:  EAA

[PezDalatoYou]

They have lots of LinkedIn posts on PMX/polymyxin/Tigris trial/etc.